A two-cohort phase i study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 3, 2013, Pages 250-253

  Raftery, Laura ^a   Tepper, Joel E ^a   Goldberg, Richard M ^a   Blackstock, A William ^a   Aklilu, Mebea ^b   Bernard, Stephen A ^a   Ivanova, Anastasia ^c   Davies, Janine M ^a   O'Neil, Bert H ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

gemcitabine; locally advanced pancreatic cancer; oxaliplatin; radiotherapy

Indexed keywords

ERLOTINIB; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; SIDE EFFECT; THERAPY DELAY; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; QUINAZOLINES; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84878876390     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182467f22     Document Type: Article

References (15)

1. Russo S, Butler J, Ove R, et al. Locally advanced pancreatic cancer: a review. Semin Oncol. 2007;34:327-334.
2. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009;27:5660-5669.
3. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801-808.
4. Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34: 107-116.
5. Mattiucci GC, Morganti AG, Valentini V, et al. External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. Int J Radiat Oncol Biol Phys. 2010;76:831-838.
6. Moschidis A, Papageorgiou A, Atmatzidis K, et al. Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice. Chemotherapy. 2007;53: 153-159.
7. Alberts SR, Townley PM, Goldberg RM, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol. 2003;14:580-585.
8. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002;20: 1512-1518.
9. Mavroudis D, Pappas P, Kouroussis C, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol. 2003;14:304-312.
10. Desai SP, Ben-Josef E, Normolle DP, et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol. 2007;25:4587-4592.
11. Laurent S, Monsaert E, Boterberg T, et al. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. Ann Oncol. 2009;20: 1369-1374.
12. Ko AH, Dito E, Schillinger B, et al. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006;24:379-385.
13. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol. 2005;28:570-575.
14. Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol. 2008;19:86-91.
15. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638-1644.